Aurelio Hernandez Lain’s research while affiliated with Hospital Universitario 12 de Octubre and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (9)


Characterization of Chitinase 3-like protein 1 spatiotemporal distribution in human post-traumatic brain contusions and other neuropathological scenarios
  • Article

January 2025

·

10 Reads

Journal of Neuropathology and Experimental Neurology

·

·

Aurelio Hernández Laín

·

Chitinase 3-like protein 1 (CHI3L1) is emerging as a promising biomarker for assessing intracranial lesion burden and predicting prognosis in traumatic brain injury (TBI) patients. Following experimental TBI, Chi3l1 transcripts were detected in reactive astrocytes located within the pericontusional cortex. However, the cellular sources of CHI3L1 in response to hemorrhagic contusions in human brain remain unidentified. Hence, we examined a comprehensive collection of histologically defined acute and subacute human cerebral contusions with various surgical intervals using immunohistochemistry, validated through double immunofluorescence for markers such as GFAP, NeuN, MBP, and Iba-1, along with Fluoro-Jade C histofluorescence staining. CHI3L1 was found at meningeal interfaces, showing significant thickening of subpial glial plate. Paradoxically, CHI3L1-positive astrocytes were identified in neuroanatomical locations distant from hemorrhagic foci, where numerous eosinophilic ischemic neurons also exhibited CHI3L1 immunoreactivity. CHI3L1 immunostaining extended into white matter tracts and highlighted various phagocytic or activated microglia forms after delayed surgical decompressions. Given these findings, we advise against using CHI3L1 as a reactive astrogliosis marker due to its expression in multiple cell types, including astrocytes, neurons, oligodendrocytes, ependymocytes, leptomeningeal cells, microglia, and blood vessels. This non-selective response underscores the potential for CHI3L1 elevation patterns in biofluids to reflect the overall lesion burden extent.


Retrocerebellar Ependymal Cyst Presenting with Obstructive Hydrocephalus in an Infant

October 2020

·

17 Reads

Journal of Pediatric Neurology

·

·

Aurelio Hernandez Lain

·

[...]

·

Intracranial ependymal cysts (ECs) are rare benign lesions. They are frequently asymptomatic and arise in the supratentorial regions. Retrocerebellar ECs is a rare location. We present a case of 3-months-old infant who developed obstructive hydrocephalus, bulging fontanel, and macrocephaly secondary to a retrocerebellar EC. Magnetic resonance imaging (MRI) showed a large retrocerebellar cyst that compressed the cerebellum and the brainstem, producing fourth ventricle outlet obstruction and supratentorial hydrocephalus. Microsurgical fenestration of the cyst to the obex of the fourth ventricle and a cystic wall biopsy were performed. The procedure improved supratentorial hydrocephalus, as well as the patient's clinical condition. A histopathological study confirmed the diagnosis of an EC. As far as we know, after a thorough review of the literature, this is the first reported case of retrocerebellar EC. It is a rare cause of hydrocephalus due to outlet obstruction of the fourth ventricle. Treatment of the cause itself has been shown to be effective.


Calf hypertrophy. Image of calf hypertrophy in patient 8
Muscle biopsy. Hematoxylin and eosin (H&E) staining of muscle biopsies from patient 1 (a) and 20 (d) showing slight regenerative changes and an isolated necrotic fiber. H&E staining of muscle biopsy from patient 7 showing a small inflammatory focus (b) and a negative staining for HLA class I (MHC-I) (e). Muscle biopsy of patient 2 showing prominent inflammation in H&E staining (c) and a positive HLA staining (f)
Muscle MRI. Muscle MRI at calf level (patient 3) showing incipient pathological changes in medial gastrocnemius muscles bilaterally (right > left), absent in T1 sequences (a) and detectable only in STIR sequences (d). Muscle MRI at thigh level (patient 2) showing more apparent and extensive muscular involvement in STIR (e) compared with T1 sequences (b); there is an asymmetric involvement of both adductors and semimembranous muscles (right > left) in T1 sequences, and a more extensive involvement of the posterior compartment of the right thigh in STIR sequences, preserving only gracilis and sartorius muscles. Control muscle MRI at thigh level (patient 2) after a period of three years showing progression of the radiological involvement of the posterior compartment of the thighs asymmetrically, appreciable in T1 sequences (c) and more apparent in STIR sequences (f); gracilis and sartorius muscles remain intact
Persistent asymptomatic or mild symptomatic hyperCKemia due to mutations in ANO5: the mildest end of the anoctaminopathies spectrum
  • Article
  • Publisher preview available

September 2020

·

2,564 Reads

·

16 Citations

Journal of Neurology

Background The ANO5 gene encodes for anoctamin-5, a chloride channel involved in muscle cell membrane repair. Recessive mutations in ANO5 are associated with muscular diseases termed anoctaminopathies, which are characterized by proximal or distal weakness, or isolated hyperCKemia. We present the largest series of patients with asymptomatic/paucisymptomatic anoctaminopathy reported so far, highlighting their clinical and radiological characteristics.Methods Twenty subjects were recruited retrospectively from the Neuromuscular Disorders Units database of two national reference centers. All had a confirmed genetic diagnosis (mean age of diagnosis was 48 years) established between 2015 and 2019. Clinical and complementary data were evaluated through clinical records.ResultsNone of the patients complained about weakness or showed abnormal muscular balance. Among paucisymptomatic patients, the main complaints or findings were generalized myalgia, exercise intolerance and calf hypertrophy, occasionally associated with calf pain. All patients showed persistent hyperCKemia, ranging from mild-moderate to severe. Muscle biopsy revealed inflammatory changes in three cases. Muscle magnetic resonance imaging revealed typical signs (preferential involvement of adductor and gastrocnemius muscles) in all but one patient. In two cases, abnormal findings were detectable only in STIR sequences (not in T1). Three patients showed radiological progression despite remaining asymptomatic. Twelve different mutations in ANO5 were detected, of which seven are novel.Conclusions Recessive mutations in ANO5 are a frequent cause of undiagnosed asymptomatic/paucisymptomatic hyperCKemia. Patients with an apparent indolent phenotype may show muscle involvement in complementary tests (muscle biopsy and imaging), which may progress over time. Awareness of anoctaminopathy as the cause of nonspecific muscular complaints or of isolated hyperCKemia is essential to correctly diagnose affected patients.

View access options

Characteristic interphalangeal contractures (a) and cigarette paper scars (b). Typical muscle MRI findings of Bethlem myopathy in T1-weighted sequence showing concentric involvement of vastus lateralis and central high signal in rectus femoris (c), as well as peripheral involvement of medial gastrocnemius muscle (d). Hematoxylin-eosin staining of muscle biopsy showing moderate dystrophic changes (e). Normal collagen VI immunohistochemical staining on muscle biopsy (f)
Bethlem myopathy: a series of 16 patients and description of seven new associated mutations

April 2019

·

351 Reads

·

17 Citations

Journal of Neurology

Background Bethlem myopathy represents the milder phenotype of collagen type VI-related myopathies. However, clinical manifestations are highly variable among patients and no phenotype-genotype correlation has been described. We aim to analyse the clinical, pathological and genetic features of a series of patients with Bethlem myopathy, and we describe seven new mutations. Methods A series of 16 patients with the diagnosis of Bethlem myopathy were analyzed retrospectively from their medical records for clinical, creatine kinase (CK), muscle biopsy, and muscle magnetic resonance (MRI) data. Genetic testing was performed through next-generation sequencing of custom amplicon-based targeted genes panel of myopathies. Mutations were confirmed by Sanger sequencing. Results The most frequent phenotype consisted of proximal limb weakness associated with interphalangeal and wrists contractures. However, cases with isolated contractures or isolated myopathy were found. CK levels did not correlate with severity of the disease. The most frequent mutation was the COL6A3 variant c.7447A>G, p.Lys2486Glu, with either an homozygous or compound heterozygous presentation. Five new mutations were found in COL6A1 gene and other two in COL6A3 gene, all of them with a dominant heritability pattern. From these, a new COL6A1 mutation (c.1657G>A, p.Glu553Arg) was related to an oligosymptomatic phenotype with predominating contractures in the absence of weakness and a normal muscle MRI. Finally, the most common COL6A1 mutation reported to date that leads to an Ullrich phenotype (c. 868G>A, p.Gly290Arg), has been found here as Bethlem presentation. Conclusions Manifestations of Bethlem myopathy are quite variable, so either contractures or weakness may be lacking, and no phenotype-genotype associations can be brought.



Calf pseudohipertrophy

April 2016

·

17 Reads

·

1 Citation

Calf pseudohypertrophy due to radiculopathy is an exceptional phenomenon rarely described. We report a 67 year old woman with a previous history of lumbar disc surgery consulting by progressive increase for more than a year of evolution painless right calf associated loss of strength. Electromyographic findings showed chronic S1 radiculopathy and radiologically was appreciated in the medial gastrocnemius and soleus rights substitution of normal muscle tissue by adipose tissue without evidence of myopathy or sarcomatous degeneration. Copyright © 2016 Elsevier España, S.L.U. y Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.


Figure 1: Characteristic morphological alterations of skeletal muscle. (A) Hematoxylin–eosin (HE) staining showing bluish inclusions in muscle fibers (arrows). (B) The inclusions contain periodic acid–Schiff (PAS)-positive material (arrows), and some fibers lack normal intermyofibrillar glycogen (asterisk). (C) The storage material is partially resistant to alpha-amylase treatment (arrows). (D–F) The storage material (arrows) is stained with antibodies for desmin, P62/SQSTM1, and ubiquitin. Scale bars in A–F correspond to 5µm. (G, H) Electron microscopy demonstrating abnormal glycogen presenting with ovoid structures composed of partly filamentous material surrounded by a rim of more dense glycogen granules and mitochondria.
Figure 2: Genetic and protein analyses. (A) Schematic illustration of the coding and noncoding region of the gene GYG1 (NM_004130). Detected variants are marked in different colors for each patient (P1, light blue; P2, green; P3, orange; P4, red; P5, yellow; P6, purple; P7, dark blue). (B) Reverse transcriptase polymerase chain reaction products covering exons 1 to 4. Lane 1: size ladder; lane 2: control sample with wild-type sequence; lane 3: patient homozygous for the GYG1 c.143+3G>C variant resulting in transcripts with skipping of exon 2; lane 4: patient heterozygous for the GYG1 c.143+3G>C variant, showing 2 bands, 1 of normal size and 1 with aberrant splicing with exon 2 skipping (lower band). (C) Schematic illustration of the consequences of incorrect splicing. The GYG1 c.143+3G>C variant results in skipping of exon 2. (D) Normally spliced transcript. (E) Aberrantly spliced transcript with exon 2 skipping. (F) Results of Western blot analysis of glycogenin-1 in skeletal muscle from a normal control (WT) and patients (P1, P4, P5, P6, and P7) performed with (+) and without (−) alpha-amylase treatment. After alpha-amylase treatment, glycogenin-1 was detected in P1, P5, and P7, demonstrating that these patients produce some residual glycogenin-1. Without alpha-amylase treatment, free glycogenin-1 was detected in P7. (G) Western blot analysis of a normal control, P7, and a patient with glycogen synthase deficiency. The glycogenin-1 detected in P7 as well as in the glycogen synthase–deficient patient revealed a gel shift corresponding to approximately 1kDa, indicating that it was autoglucosylated. Glycogenin-1 in P7 is reduced in size due to the truncating variant. (H) Western blot analyses of glycogen synthase (GYS1) and branching enzyme (GBE1) in P1, P4, P5, P6, P7, 1 patient with GYS1 deficiency, and 1 with RBCK1 deficiency. No obvious upregulation or downregulation of these enzymes was evident in patients with pathogenic GYG1 variants. (I) In vitro autoglucosylation demonstrated that glycogenin-1 in P3 and P4 was unable to autoglucosylate when uridine diphosphate (UDP) glucose was added (+). The truncated glycogenin-1 in P7 increased in size when UDP glucose was added, showing that it was autoglucosylated.
A New Muscle Glycogen Storage Disease Associated with Glycogenin-1 Deficiency

December 2014

·

332 Reads

·

81 Citations

Annals of Neurology

We describe a slowly progressive myopathy in seven unrelated adult patients with storage of polyglucosan in muscle fibers. Genetic investigation revealed homozygous or compound heterozygous deleterious variants in the glycogenin-1 gene (GYG1). Most patients showed depletion of glycogenin-1 in skeletal muscle whereas one showed presence of glycogenin-1 lacking the C-terminal that normally binds glycogen synthase. Our results indicate that either depletion of glycogenin-1 or impaired interaction with glycogen synthase underlies this new form of glycogen storage disease that differs from a previously reported patient with GYG1 mutations who showed profound glycogen depletion in skeletal muscle and accumulation of glycogenin-1. ANN NEUROL 2014. © 2014 American Neurological Association


Is there a clinical or radiological correlate to the histological evidence of an inflammatory infiltrate in the herniated disc? Results of a consecutive series of patients surgically treated of herniated lumbar disc

July 2014

·

12 Reads

Trauma (Spain)

Objective: To establish the clinical relevance of the histological evidence of inflammatory cell infiltrates in surgical samples of operated lumbar disc hernia. Material and method: Surgical samples, clinical, and epidemiological data were obtained from 50 patients consecutively operated on of lumbar disc herniation during 2012 were obtained. Also the MR appearance as extruded or contained hernia was recorded. All samples were processed using hematoxilin-eosin staining and different histological parameters were determined such as the presence and quantity of chondrocytes present in the disc as a sign of disc degeneration. Results: Even though the majority of samples examined showed signs of disc degeneration, such as the presence of chondrocyte proliferation, the evidence of neovascularisation or inflammatory infiltrates was scarce. The presence of inflammatory infiltrates was invariably related to the presence of neovascularisation. However, the presence of inflammatory infiltrates was not related to any radiological or clinical variable. Conclusion: There is no relation between the presence of inflammatory infiltrates and the clinical data registered. The presence of histological evidence of inflammation in herniated lumbar disc tissue is not related to disc degeneration or the presence of pain.


Citations (5)


... The role of muscle MRI in asymptomatic hyperCKemia remains underexplored, with few reports focusing on adult or anecdotal cases. 39 indicative of presymptomatic stages. This study demonstrated that MRI is useful for detecting underlying inflammatory disorders but has a low predictive value for the diagnosis of asymptomatic hyperCKemia. ...

Reference:

Asymptomatic HyperCKemia in the Pediatric Population: A Prospective Study Utilizing Next-Generation Sequencing and Ancillary Tests
Persistent asymptomatic or mild symptomatic hyperCKemia due to mutations in ANO5: the mildest end of the anoctaminopathies spectrum

Journal of Neurology

... Of note is that the CK level in most reported cases of BM ranges from normal to slightly elevated. It has been reported that CK levels do not correlate with disease severity [42,43]. In contrast, in spinal muscular atrophy (SMA), a motor neuron disease, CK levels are consistently elevated and have a prognostic value [44]. ...

Bethlem myopathy: a series of 16 patients and description of seven new associated mutations

Journal of Neurology

... The first is true hypertrophy, where the muscle fibers themselves enlarge, and muscle biopsy shows a mixed pattern of enlarged muscle fibers with a large cross-sectional area and small atrophied muscle fibers [11]. The second type is pseudohypertrophy, where muscle fibers are replaced by other tissues, and muscle biopsy and MRI show muscle fibers replaced by adipose tissue and infiltration of inflammatory cells [7,13]. Two hypotheses for true hypertrophy and one hypothesis for pseudohypertrophy have been proposed. ...

Calf pseudohipertrophy
  • Citing Article
  • April 2016

... Glycogenin-1, an enzyme involved in the biosynthesis of glycogen, encoded by the GYG1 gene, and mutations have been described in GSD XV. Muscle biopsy showed reduced glycogen, mitochondrial proliferation, and type I fiber predominance [112]; a case report in 7 patients with Glyvogenin-1 deficiency showed progressive proximal weakness, a myopathic EMG, and polyglucosan bodies in the muscle biopsy [41]. In GSD V, the enzyme myophosphorylase catalyzes the rate-limiting step in muscle glycogen metabolism by releasing glucose-1-phosphate from terminal alpha-1,4-glycosidic bonds. ...

A New Muscle Glycogen Storage Disease Associated with Glycogenin-1 Deficiency

Annals of Neurology

... [2][3][4] Tanycytic ependymoma is an uncommon subtype of WHO grade 2 ependymoma; even though which commonly found in the cervical and thoracic spinal cord, they are also found in the brainstem, conus medullaris, intraventricular, and even extramedullary region. [4][5][6][7][8][9][10][11][12][13] In this unique subtype, ependymal rosettes and perivascular pseudorosettes are replaced by more fibrillary cells when compared with classic ependymomas. Thus, it makes the diagnosis much more tricky and may lead to misdiagnosis as schwannoma or pilocytic astrocytoma. ...

Spinal tanycytic ependymoma associated with neurofibromatosis type 2
  • Citing Article
  • February 2014

Clinical Neuropathology